Sandra S. Pinhanços

The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis

P Garrido Castro, Eddy H.J. Van Roon, Sandra S. Pinhanços et al. · Leukemia · 2017 · 73 citations

Hematological Malignancy, Tumor Biology, Rnf20/rnf40/wac-h2b Ubiquitination Axis +10

Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia

J A P Spijkers-Hagelstein, Sandra S. Pinhanços, Pauline Schneider et al. · Leukemia · 2012 · 67 citations

Hematological Malignancy, Signal Transduction, Mixed-phenotype Acute Leukemia +11

MEK inhibition is a promising therapeutic strategy for <i>MLL</i>-rearranged infant acute lymphoblastic leukemia patients carrying <i>RAS</i> mutations

Mark Kerstjens, Emma M. C. Driessen, Merel Willekes et al. · Oncotarget · 2016 · 43 citations · Full text

AMP-activated Protein Kinase Activation by 5-Aminoimidazole-4-carbox-amide-1-β-d-ribofuranoside (AICAR) Reduces Lipoteichoic Acid-induced Lung Inflammation

Arie J. Hoogendijk, Sandra S. Pinhanços, Tom van der Poll et al. · Journal of Biological Chemistry · 2013 · 37 citations · Full text

Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL

J A P Spijkers-Hagelstein, Sandra S. Pinhanços, Pauline Schneider et al. · Leukemia · 2013 · 37 citations

Genetic Analysis, Allelic Variant, Genetic Disorder +9